Evidence map›Paper›PMID 38329790›Full record

ArticleJMIR research protocols2024

Role of Chinese Acupuncture in the Treatment for Chemotherapy-Induced Cognitive Impairment in Older Patients With Cancer: Protocol for a Randomized Controlled Trial.

Sunyan Zhao, Jing Zhang, Haijun Wan, Chenjie Tao, Meng Hu, Wei Liang, Zhi Xu, Bingguo Xu, Jiaying Zhang, Guoxin Wang and 3 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JMIR research protocols, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05876988 (The Role of Chinese Acupuncture for Chemotherapy Induced Cognitive Impairment in Elderly Cancer Patients), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05876988 naunknown statusnot on this map

The Role of Chinese Acupuncture for Chemotherapy Induced Cognitive Impairment in Elderly Cancer Patients

TypeinterventionalSponsorNanjing First Hospital, Nanjing Medical UniversityRan2023 to 2025Enrolled168ConditionsChinese AcupunctureArmsChinese acupuncture
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Sunyan Zhao *Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0009-0006-1582-5250
Jing Zhang *Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0009-0009-3831-6143
Haijun Wan *Department of Gastroenterology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.ORCID https://orcid.org/0009-0000-1125-4338
Chenjie TaoDepartment of Oncology, Eastern Hepatobiliary Hospital, Naval Medical University, Shanghai, China.ORCID https://orcid.org/0000-0001-6077-9472
Meng HuDepartment of Medical Oncology, Liyang People's Hospital, Liyang, China.ORCID https://orcid.org/0009-0005-1291-4082
Wei LiangDepartment of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0000-0003-1619-5116
Zhi XuMedical Affairs, ICON Public Limited Company (ICON Plc), Beijing, China.ORCID https://orcid.org/0000-0001-7228-408X
Bingguo XuDivision of Chinese Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0009-0005-3510-3741
Jiaying ZhangDivision of Chinese Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0009-0005-9290-000X
Guoxin WangDivision of Chinese Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0000-0001-7619-8197
Ping Li *Department of Gastroenterology, Changhai Hospital, Naval Medical University, Shanghai, China.ORCID https://orcid.org/0009-0005-3784-0999
Guangmei Lyu *Information Centre, Jiangsu Health Vocational College, Nanjing, China.ORCID https://orcid.org/0009-0003-0068-7279
Yongling Gong *Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0000-0002-7954-7855
Nanjing Medical University · CNSecond Military Medical University · CNImperial Consultants · GBJiangsu Vocational College of Medicine · CNNanjing General Hospital of Nanjing Military Command · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOlder patients with cancer experience cognitive impairment and a series of neurocognitive symptoms known as chemobrain due to chemotherapy. Moreover, older populations are disproportionately affected by chemobrain and heightened negative mental health outcomes after cytotoxic chemical drug therapy. Chinese acupuncture is an emerging therapeutic option for chemotherapy-induced cognitive impairment in older patients with cancer, despite limited supporting evidence.

objectiveOur study aims to directly contribute to the existing knowledge of this novel Chinese medicine mode in older patients with cancer enrolled at the Department of Oncology/Chinese Medicine, Nanjing First Hospital, China, thereby establishing the basis for further research.

methodsThis study involves a 2-arm, prospective, randomized, assessor-blinded clinical trial in older patients with cancer experiencing chemobrain-related stress and treated with Chinese acupuncture from September 30, 2023, to December 31, 2025. We will enroll 168 older patients with cancer with clinically confirmed chemobrain. These participants will be recruited through screening by oncologists for Chinese acupuncture therapy and evaluation. Electroacupuncture will be performed by a registered practitioner of Chinese medicine. The electroacupuncture intervention will take about 30 minutes every session (2 sessions per week over 8 weeks). For the experimental group, the acupuncture points are mainly on the head, limbs, and abdomen, with a total of 6 pairs of electrically charged needles on the head, while for the control group, the acupuncture points are mainly on the head and limbs, with only 1 pair of electrically charged needles on the head.

resultsEligible participants will be randomized to the control group or the experimental group in 1:1 ratio. The primary outcome of this intervention will be the scores of the Montreal Cognitive Assessment. The secondary outcomes, that is, attentional function and working memory will be determined by the Digit Span Test scores. The quality of life of the patients and multiple functional assessments will also be evaluated. These outcomes will be measured at 2, 4, 6, and 8 weeks after the randomization.

conclusionsThis efficacy trial will explore whether Chinese electroacupuncture can prevent chemobrain, alleviate the related symptoms, and improve the quality of life of older patients with cancer who are undergoing or are just going to begin chemotherapy. The safety of this electroacupuncture intervention for such patients will also be evaluated. Data from this study will be used to promote electroacupuncture application in patients undergoing chemotherapy and support the design of further real-world studies.

trial registrationClinicalTrials.gov NCT05876988; https://clinicaltrials.gov/ct2/show/NCT05876988. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/53853.

Indexed as

chemobrainChinese medicinecognitive impairmentelectroacupunctureolder patients with cancer

Identifiers

PMID38329790
PMCPMC10884956
OpenAlexW4390758630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.